AR100132A1 - Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino - Google Patents
Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femeninoInfo
- Publication number
- AR100132A1 AR100132A1 ARP150101170A ARP150101170A AR100132A1 AR 100132 A1 AR100132 A1 AR 100132A1 AR P150101170 A ARP150101170 A AR P150101170A AR P150101170 A ARP150101170 A AR P150101170A AR 100132 A1 AR100132 A1 AR 100132A1
- Authority
- AR
- Argentina
- Prior art keywords
- female subject
- fsh
- preparation
- stimulate
- development
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000002611 ovarian Effects 0.000 title 1
- 210000000287 oocyte Anatomy 0.000 abstract 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 abstract 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 abstract 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 229950006780 n-acetylglucosamine Drugs 0.000 abstract 1
- 210000002394 ovarian follicle Anatomy 0.000 abstract 1
- 230000016087 ovulation Effects 0.000 abstract 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 1
- 125000005629 sialic acid group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
- A61B17/43—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for artificial insemination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un método para la hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino, que comprende (a) administrar a un sujeto femenino una preparación de FSH recombinante utilizando un régimen de dosificación en donde las dosis individuales suman hasta una cantidad promedio de aproximadamente 35 a aproximadamente 250 UI de FSH por día; (b) activar la ovulación cuando hay múltiples folículos con un diámetro medio igual a o mayor que 12 mm. y/o cuando hay al menos un folículo con un diámetro de al menos 17 mm.; (c) obtener múltiples ovocitos del sujeto femenino, en donde en promedio se obtienen al menos 5 ovocitos por sujeto femenino y/o se obtienen al menos 5 ovocitos del sujeto femenino; en donde la FSH recombinante en la preparación tiene un patrón de glicosilación que comprende las siguientes características: (i) una cantidad relativa de glicanos que portan N-acetilglucosamina de bisección (bisGlcNAc) de al menos 20% de todos los glicanos unidos a la FSH en la preparación; y (ii) una cantidad relativa de ácido siálico en enlace 2,6 de al menos 40% de todos los residuos de ácido siálico unidos a la FSH en la preparación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461981621P | 2014-04-18 | 2014-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100132A1 true AR100132A1 (es) | 2016-09-14 |
Family
ID=53015773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101170A AR100132A1 (es) | 2014-04-18 | 2015-04-17 | Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170035854A1 (es) |
| EP (1) | EP3131571A1 (es) |
| JP (1) | JP2017513853A (es) |
| KR (1) | KR20160144480A (es) |
| CN (1) | CN106413735A (es) |
| AR (1) | AR100132A1 (es) |
| AU (1) | AU2015248793A1 (es) |
| BR (1) | BR112016023668A2 (es) |
| CA (1) | CA2945883A1 (es) |
| IL (1) | IL248362A0 (es) |
| MX (1) | MX2016013449A (es) |
| SG (1) | SG11201608132UA (es) |
| WO (1) | WO2015158875A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| WO2018080120A1 (en) * | 2016-10-28 | 2018-05-03 | Samsung Electronics Co., Ltd. | Method and apparatus for follicular quantification in 3d ultrasound images |
| US11744879B2 (en) * | 2017-09-01 | 2023-09-05 | Ferring B.V. | Recombinant FSH composition for controlled ovarian stimulation |
| CN110570952B (zh) * | 2018-06-05 | 2022-04-12 | 北京大学第三医院 | 预测拮抗剂方案下受试者卵巢低反应概率的系统及指导促性腺激素起始用药剂量选择的系统 |
| CN112603990B (zh) * | 2020-12-17 | 2022-03-08 | 广州医药研究总院有限公司 | 提高犬卵巢卵丘-卵母细胞复合体数量的试剂盒及其应用 |
| US20240285250A1 (en) * | 2023-02-23 | 2024-08-29 | Urmila Diwekar | Systems and Methods for Personalized Medicine in IVF for Reduced Dosage and Testing, and Better Outcomes |
| CN116798634B (zh) * | 2023-08-25 | 2023-11-21 | 北京大学深圳医院 | 一种fsh启动剂量预测系统、电子设备及存储介质 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2261740T3 (es) | 2001-10-22 | 2006-11-16 | Applied Research Systems Ars Holding N.V. | Composiciones de fsh con alto grado de sialilacion y su uso para la preparacion de medicamentos. |
| SG178925A1 (en) * | 2009-09-22 | 2012-04-27 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| EP2325194A1 (en) | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
| WO2012016576A1 (en) | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
-
2015
- 2015-04-17 AR ARP150101170A patent/AR100132A1/es unknown
- 2015-04-17 WO PCT/EP2015/058352 patent/WO2015158875A1/en not_active Ceased
- 2015-04-17 EP EP15719165.1A patent/EP3131571A1/en not_active Withdrawn
- 2015-04-17 KR KR1020167031711A patent/KR20160144480A/ko not_active Withdrawn
- 2015-04-17 US US15/303,703 patent/US20170035854A1/en not_active Abandoned
- 2015-04-17 AU AU2015248793A patent/AU2015248793A1/en not_active Abandoned
- 2015-04-17 CN CN201580020167.7A patent/CN106413735A/zh active Pending
- 2015-04-17 SG SG11201608132UA patent/SG11201608132UA/en unknown
- 2015-04-17 MX MX2016013449A patent/MX2016013449A/es unknown
- 2015-04-17 BR BR112016023668A patent/BR112016023668A2/pt not_active Application Discontinuation
- 2015-04-17 CA CA2945883A patent/CA2945883A1/en not_active Abandoned
- 2015-04-17 JP JP2016562890A patent/JP2017513853A/ja active Pending
-
2016
- 2016-10-13 IL IL248362A patent/IL248362A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106413735A (zh) | 2017-02-15 |
| WO2015158875A1 (en) | 2015-10-22 |
| MX2016013449A (es) | 2017-05-04 |
| BR112016023668A2 (pt) | 2017-10-17 |
| KR20160144480A (ko) | 2016-12-16 |
| IL248362A0 (en) | 2016-11-30 |
| SG11201608132UA (en) | 2016-11-29 |
| CA2945883A1 (en) | 2015-10-22 |
| JP2017513853A (ja) | 2017-06-01 |
| EP3131571A1 (en) | 2017-02-22 |
| US20170035854A1 (en) | 2017-02-09 |
| AU2015248793A1 (en) | 2016-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100132A1 (es) | Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino | |
| CL2020000498A1 (es) | Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920) | |
| CL2018000232A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
| CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
| MX2015000990A (es) | Analogos del glucagon. | |
| CL2017001089A1 (es) | Vacunas terapéuticas contra el vph16 | |
| PE20181531A1 (es) | Vacuna del virus herpes simple | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
| CL2017000999A1 (es) | Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. | |
| MX2017015046A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| MX2017004211A (es) | Reglas para modos de prediccion intra-imagen cuando se habilita el procesamiento paralelo de onda frontal. | |
| MX382917B (es) | Formulaciones de proteínas líquidas que contienen líquidos iónicos. | |
| AR101742A1 (es) | Agonista del receptor de calcitonina y amilina | |
| MX384422B (es) | Vector que expresa conjuntamente vacunas y moléculas coestimuladoras | |
| CY1124734T1 (el) | Μορφες δοσολογιας αυξητικης ορμονικης μακρας δρασης | |
| AR095317A1 (es) | Sistemas y métodos para determinar una formulación de recubrimiento | |
| CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
| MX384989B (es) | Uso de un agonista del receptor x retinoide (rxr) en combinación con una hormona tiroidea para el tratamiento de esclerosis múltiple. | |
| AR116451A1 (es) | Administración oral de análogos del péptido glp-1 | |
| MX2017009812A (es) | Composiciones y metodos para inhibir infeccion viral. | |
| BR112017004739A2 (pt) | ligantes de hormônio folículo estimulante, complexo de ligante e gonadotrofina, uso de um ligante, e composição farmacêutica | |
| CL2018001104A1 (es) | Composición para el cuidado de la piel y procedimiento asociado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |